Загрузка...
Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
Lenalidomide, an oral immunomodulatory agent, has received approval in the USA from the Food and Drug Administration (FDA) for the management of myelodysplastic syndromes (MDS) classified by the International Prognostic Scoring System (IPSS) as low risk or intermediate-1 risk and with a deletion 5q...
Сохранить в:
| Главные авторы: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer-Verlag
2008
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2275303/ https://ncbi.nlm.nih.gov/pubmed/18265982 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-008-0449-0 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|